National Bioservice: Fabric microchips

2020: A possibility of the accelerated testing of antikoronavirusny medicines

The portfolio company of RVC Biofund National Bioservice gave (NBS) an opportunity of the accelerated testing of antikoronavirusny medicines and test systems on which the Russian developers work. Reduction of term of preclinical researches and technical tests will become possible due to use of fabric microchips. On March 24, 2020 reported about it to RVC.

National Bioservice became the first company which organized production of fabric microchips in Russia. Microchips are a set of different fabrics which is packed on a special substrate. Earlier, to look how medicine interacts with 60 samples of fabrics, it was necessary to make not less than 60 experiments. Now this set of fabrics can be placed on one microchip and to receive exact results for one experiment. On average on development of vaccines several years leave, terms of development of medicines can reach 10 years. Fabric microchips allow to pass some test stages of drugs much quicker.

NBS makes fabric microchips of different design, including the special microchip for testing of cross-reactivity of antibodies allowing to estimate security of the tested medicine. For March, 2020 before medicine there were modern calls, and we represent almost ready tool for rapid response to the requirements arising at developers of medicines and tests. When the science and health care are faced by relevant and important research problems of strategic scale, NBS invites partners to use the resources and competences for accomplishment of joint projects, told Vitaly Prutsky, the CEO National Bioservice

Annually undergoes about 200 clinical trials using fabric microchips in the world, their cost fluctuates in the range from 60 to 120 thousand dollars. It is important that NBS released a domestic product which including many times reduces the price of the cost of researches. The project has enough resources to satisfy requirements of the Russian biopharmaceutical companies, and in the long term to enter also the world market,

NBS executes orders of many leading domestic and foreign biopharmaceutical companies, research institutes on design, production and use of fabric microchips on own laboratory base. In 2017-18 by request of FNITs of epidemiology and microbiology of N.F. Gamalei NBS took active part in development of the Russian drug against fever Ebola. The company conducted a preclinical research of cross-reactivity of this medicine.